OneSource Specialty Pharma Ltd is a fast-growing biologics-focused contract development and manufacturing organization (CDMO) offering end-to-end services for pre-clinical, clinical, and commercial production of injectable biologic drugs. Backed by its parent Strides Pharma and recent regulatory milestones—including Saudi FDA approval for generic semaglutide—the company has reported explosive sales growth of 656% and turned profitable in FY2025. However, it remains a high-risk, early-stage play with low return ratios and significant promoter pledging. This article provides a fact-based outlook on its share price target for each year from 2026 through 2030.
OneSource Specialty Pharma: Company Overview
- Incorporated: 2007; listed in 2024
- Core Business:
- CDMO for biologics (mammalian & microbial platforms)
- Manufacturing of pre-filled syringes, vials, and cartridges
- End-to-end support: tech transfer, regulatory filings, commercial supply
- Key Milestones:
- Approved to produce generic semaglutide (GLP-1 analog) for Hikma in the MENA region
- Operates state-of-the-art facilities in Bengaluru
- Serves global biopharma clients across the US, Europe, and the Middle East
- Ownership: 29.93% held by promoters (Strides Pharma group); promoter pledging at 18.52% as of Dec 2025
OneSource Specialty Pharma: Key Financial Snapshot
| Metric | Value |
|---|---|
| Market Capitalization | ₹15,009.65 Cr |
| Current Share Price | ₹1,310 (as of Feb 2026) |
| P/E (TTM) | 85.96 |
| P/B (TTM) | 2.53 |
| Book Value (TTM) | ₹516.97 |
| EPS (TTM) | ₹15.23 |
| ROE | 0.64% |
| ROCE | 3.66% |
| Dividend Yield | 0% |
| Sales Growth (TTM) | 655.93% |
| Profit Growth (TTM) | 105.48% |
| Cash Reserves | ₹227.62 Cr |
| Debt | ₹771.59 Cr |
| Face Value | ₹1 |
OneSource Share Price Target Forecast (2026–2030)
| Year | Target Price Range (₹) |
|---|---|
| 2026 | ₹1,400 – ₹1,650 |
| 2027 | ₹1,550 – ₹1,900 |
| 2028 | ₹1,700 – ₹2,200 |
| 2029 | ₹1,850 – ₹2,500 |
| 2030 | ₹2,000 – ₹2,800 |
Targets assume successful scale-up of semaglutide and other biologics contracts—not immediate margin expansion.
OneSource Share Price Target 2026
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2026 | ₹1,400 | ₹1,650 |
- High P/E (86x) reflects early optimism, not earnings strength
- Upside depends on Q4 FY2026 execution and new client wins
- Risk: Low ROCE (3.7%) and high debt limit valuation upside
OneSource Share Price Target 2027
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2027 | ₹1,550 | ₹1,900 |
- Potential support from semaglutide commercial shipments to MENA
- Regulatory success could attract more GLP-1 and biosimilar partnerships
- No dividend expected; reinvestment remains priority
OneSource Share Price Target 2028
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2028 | ₹1,700 | ₹2,200 |
- By 2028, the cumulative effect of biologics funnel conversion should reflect in margins
- Valuation may stabilize if ROCE crosses 8%
- Execution risk: Biologics manufacturing is capital-intensive and highly regulated
OneSource Share Price Target 2029
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2029 | ₹1,850 | ₹2,500 |
- Long-term tailwinds from the global biologics outsourcing boom
- Debt-to-equity remains high, but cash flow from contracts may improve
- Institutional ownership (~38%) provides moderate liquidity
OneSource Share Price Target 2030
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2030 | ₹2,000 | ₹2,800 |
- ₹2,800 is achievable only if ROCE sustains above 10% and debt is reduced
- Realistically, the stock will trade in a wide band until consistent profitability is proven
- Targets beyond ₹3,000 are not credible without major new product approvals
OneSource Specialty Pharma: Shareholding Pattern
| Category | Holding (%) |
|---|---|
| Public (Retail) | 32.15% |
| Promoters | 29.93% |
| Foreign Institutions (FII) | 19.24% |
| Domestic Institutions (DII) | 18.68% |
| Others | 0% |
Promoter pledging is high (18.52% as of Dec 2025), which increases downside risk during market stress.
OneSource Specialty Pharma: Strengths vs Risks
Strengths
- First-mover in India for semaglutide biosimilar manufacturing
- Strong parent backing (Strides Pharma)
- Explosive top-line growth (656% sales jump)
- Global regulatory approvals (SFDA, USFDA audits)
Risks
- Extremely low ROE (0.64%) and ROCE (3.66%)
- High debt (₹772 Cr) vs low cash (₹228 Cr)
- Significant promoter pledging (18.5%)
- No dividend history—offers zero income cushion
Investment Suitability
| Factor | Assessment |
|---|---|
| Risk Profile | Very High |
| Time Horizon | Long-term (5+ years) |
| Volatility | High |
| Dividend/Income | None (0% yield) |
| Ideal Investor | Speculative investor betting on India’s biologics CDMO potential, comfortable with high pledging and low returns |
FAQs
A: A realistic range is ₹1,400 to ₹1,650, assuming continued commercial momentum.
A: Credible estimates suggest ₹2,000 to ₹2,800 by 2030—if biologics scale and returns improve.
A: Reliable forecasts beyond 2030 are not possible. Such long-term projections are speculative and not based on verifiable data.
A: The Strides Pharma group holds 29.93% as promoters. The rest is widely held by institutions and public shareholders.
A: No. The company has never declared a dividend and currently offers 0% yield.
A: The stock corrected due to high pledging concerns, low ROCE, and profit-taking after its listing rally in 2024–2025.
A: No. It carries ₹771.59 crore in debt, significantly higher than its cash reserves of ₹227.62 crore.
Final Verdict
OneSource Specialty Pharma is a high-potential but high-risk biologics CDMO with a breakthrough in semaglutide manufacturing. While its sales explosion is real, its capital inefficiency and promoter pledging make current valuations speculative. Our 2026–2030 price targets (₹1,400–₹2,800) reflect cautious optimism—rewarding innovation but capping upside until sustainable returns emerge. Suitable only for investors with high risk tolerance and a 5-year horizon.
Disclaimer: This article is for educational purposes only. It is not investment advice. Please consult a SEBI-registered advisor before making any investment decision.
Sources
- Screener.in – OneSource Specialty Pharma Ltd (Consolidated Financials)
- Finology.in – Company Essentials
- BSE India – Shareholding & Pledging Data (Dec 2025)
- OneSource Investor Presentation – Q2 FY2026
- Company Announcement – SFDA Semaglutide Approval (Feb 11, 2026)
Hi, I’m Raj Mittal, a stock market content writer focused on company analysis, share price trends, and fundamental research. I create simple, research-based insights to help investors make smarter market decisions.
